Tarius SAC Tracker®


Background Analysis: US FDA Advisory Committee to Review Eli Lilly’s Necitumumab for Squamous Non-small Cell Lung Cancer – JUL 9, 2015 (ODAC)


The SAC Tracker report for this meeting is only available for SAC Tracker Premium subscribers.

The SAC Tracker reports are available for FREE on this site until 10 days after the meeting is held. 

To obtain unlimited access to SAC Tracker meeting reports back to 2010 and onwards, including the committee members' voting history, you must subscribe to the SAC Tracker Premium service.

Read more and subscribe here.

METADATA: Sponsor: Eli Lilly and Company Drug Name: necitumumab Drug Class: monoclonal antibody Indication: locally advanced or metastatic squamous non-small cell lung cancer